Product NDC: | 0310-0283 |
Proprietary Name: | SEROQUEL |
Non Proprietary Name: | Quetiapine fumarate |
Active Ingredient(s): | 300 mg/1 & nbsp; Quetiapine fumarate |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, EXTENDED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0310-0283 |
Labeler Name: | AstraZeneca Pharmaceuticals LP |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA022047 |
Marketing Category: | NDA |
Start Marketing Date: | 20070716 |
Package NDC: | 0310-0283-94 |
Package Description: | 4 TABLET, EXTENDED RELEASE in 1 BOTTLE (0310-0283-94) |
NDC Code | 0310-0283-94 |
Proprietary Name | SEROQUEL |
Package Description | 4 TABLET, EXTENDED RELEASE in 1 BOTTLE (0310-0283-94) |
Product NDC | 0310-0283 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Quetiapine fumarate |
Dosage Form Name | TABLET, EXTENDED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20070716 |
Marketing Category Name | NDA |
Labeler Name | AstraZeneca Pharmaceuticals LP |
Substance Name | QUETIAPINE FUMARATE |
Strength Number | 300 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Atypical Antipsychotic [EPC] |